Limb-girdle Muscular Dystrophy and Therapy: Insights into Cell and Gene-based Approaches

Area of Science:

• Neurology
• Genetics
• Molecular Biology

Background:

• Limb-Girdle Muscular Dystrophy (LGMD) encompasses genetically diverse muscle-wasting disorders.
• Current treatments for LGMD primarily manage symptoms and improve quality of life, without addressing underlying causes.
• There is a significant need for novel therapeutic strategies targeting the molecular mechanisms of LGMD.

Purpose of the Study:

• To review recent advancements in therapeutic approaches for Limb-Girdle Muscular Dystrophy.
• To discuss the potential of emerging gene-based and genome engineering strategies for LGMD treatment.
• To highlight the challenges and future directions in the clinical translation of these novel therapies.

Main Methods:

• Review of current literature on Limb-Girdle Muscular Dystrophy pathogenesis and treatment.
• Analysis of emerging therapeutic modalities including gene replacement, gene transfer, exon skipping, siRNA knockdown, and anti-myostatin therapy.
• Evaluation of genome engineering tools, particularly CRISPR-Cas9, for neuromuscular disorder applications.

Main Results:

• Despite progress in understanding LGMD, definitive curative treatments remain elusive.
• Gene therapy approaches like gene replacement and exon skipping show promise for targeting specific LGMD mechanisms.
• Genome engineering technologies, especially CRISPR-Cas9, present a high potential for clinical application in neuromuscular disorders.

Conclusions:

• Novel therapeutic strategies targeting specific molecular pathways are crucial for effective LGMD treatment.
• Gene-based therapies and genome engineering hold significant promise for the future treatment of LGMD.
• Further research and clinical translation are necessary to overcome challenges and realize the potential of these advanced therapies.